License, Commercialization And Supply Agreements (Details)	1 Months Ended				6 Months Ended
	Jun. 30, 2018 USD ($) $ / shares shares	Sep. 30, 2017 USD ($)	Nov. 30, 2013	Jul. 31, 2013 country	Jun. 30, 2018 USD ($) $ / shares shares
License, Commercialization, and Development Agreements with Third Parties
Payments to Acquire Businesses, Gross					$ 135,000,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	10 years
PANCREAZE
License, Commercialization, and Development Agreements with Third Parties
Finite-Lived License Agreements, Gross	$ 141,900,000				141,900,000
PANCREAZE | Warrants Issued
License, Commercialization, and Development Agreements with Third Parties
Fair Value Assumptions, Expected Term	7 years
Fair Value Assumptions, Expected Volatility Rate	61.60%
Fair Value Assumptions, Risk Free Interest Rate	2.91%
Fair Value Assumptions, Expected Dividend Rate	0.00%
PANCREAZE | Janssen
License, Commercialization, and Development Agreements with Third Parties
Payments to Acquire Businesses, Gross	$ 135,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other	400,000				400,000
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Accruals For Estimated Destruction Of Future Unsalable Inventory	6,300,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	$ 2,100,000				$ 2,100,000
PANCREAZE | Willow Biopharma Member
License, Commercialization, and Development Agreements with Third Parties
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	3,570,000				3,570,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.37				$ 0.37
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other	$ 1,500,000				$ 1,500,000
PANCREAZE | Willow Biopharma Member | Warrants Issued
License, Commercialization, and Development Agreements with Third Parties
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	$ 800,000
License and commercialization agreement | Menarini Group
License, Commercialization, and Development Agreements with Third Parties
Number of European countries covered under the license agreement | country				40
License and commercialization agreement | Qsymia | Alvogen
License, Commercialization, and Development Agreements with Third Parties
License and Services Revenue		$ 2,500,000
Supply agreement | Avanafil Tablets Member | Sanofi Winthrop | Minimum
License, Commercialization, and Development Agreements with Third Parties
Long-term Purchase Commitment, Period			5 years
Supply agreement | STENDRA/SPEDRA | Metuchen
License, Commercialization, and Development Agreements with Third Parties
Initial term					5 years
Additional period of auto-renewal					2 years
Supply agreement | STENDRA/SPEDRA | Metuchen | Minimum
License, Commercialization, and Development Agreements with Third Parties
Termination notice of license and supply agreement					2 years